ThePeptide Examiner
Comparison

Ozempic vs Wegovy: same drug, different label — here's what that means

Both are semaglutide. Same molecule, same manufacturer. Different approvals, different doses, different insurance outcomes. The distinction matters more than you'd think.

Editorially reviewedThe Peptide Examiner editorial team, Editorial review · Reviewed Apr 23, 2026

Ozempic and Wegovy are both brand names for semaglutide, made by Novo Nordisk. They are the same drug molecule. What differs is the FDA-approved indication (type 2 diabetes vs chronic weight management), the maximum labeled dose (2.0 mg vs 2.4 mg), and — crucially for patients — insurance coverage and off-label prescribing norms.

FieldOzempicWegovy
Brand namessemaglutidesemaglutide
ManufacturerNovo NordiskNovo Nordisk
FDA approved2017 (type 2 diabetes)2021 (chronic weight management)
IndicationType 2 diabetes; cardiovascular risk reduction in T2D adults with established CV diseaseChronic weight management in adults with BMI ≥30, or ≥27 with weight-related comorbidity; adolescents age 12+
MechanismGLP-1 receptor agonistGLP-1 receptor agonist
DeliveryOnce-weekly subcutaneous injectionOnce-weekly subcutaneous injection
Avg weight loss~6% at 40 weeks (SUSTAIN-7, T2D population, 1 mg)~14.9% at 68 weeks (STEP-1, 2.4 mg)

Primary sources

Frequently asked

Is Ozempic the same as Wegovy?

The active ingredient is identical — semaglutide. The FDA-approved indication, labeled maximum dose (2.0 mg for Ozempic, 2.4 mg for Wegovy), and patient population differ. For billing, coverage, and prescribing, they are treated as separate drugs.

Can I get Ozempic for weight loss?

It's prescribed off-label for weight loss commonly, but most insurance plans require the FDA-approved indication (T2D) to cover it. Without diabetes, coverage is inconsistent and the patient often pays out of pocket — typically $900-1,100/month.

Why would someone pick Ozempic over Wegovy?

Insurance coverage. If a patient has T2D, Ozempic is labeled and typically covered. If a patient has obesity but not T2D, Wegovy is labeled for that. Off-label prescribing can work but is often not reimbursed.

Is one more effective than the other for weight loss?

At matched doses, efficacy is identical — same molecule. Wegovy's higher FDA-approved maximum dose (2.4 mg vs Ozempic's 2.0 mg) produces slightly more weight loss simply because the dose is higher.

Which came first?

Ozempic (2017, T2D approval). Wegovy is the 2021 obesity-specific relabel at a higher maximum dose.